Why This Healthcare Giant Expects Decreased Covid Profits in 2022
Abbott (NYSE: ABT) is projecting $2.5 billion in COVID-19 testing revenue for all of 2022, a low estimate considering the company made nearly that much in the fourth quarter alone. In this segment of "This Week in Healthcare," recorded on Jan. 31, Motley Fool contributor Keith Speights talks about Abbott's future as the coronavirus pandemic starts to ease.
Source Fool.com
